Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the initiation
of a Phase II clinical trial evaluating linaclotide for the treatment of
adults suffering from opioid-induced constipation (OIC). Data are
expected in the second half of 2015.
for - Ironwood Pharmaceuticals Announces Initiation of Phase II Trial of Linaclotide in Adult Patients with Opioid-Induced Constipation investment picks